YMAB - Y mAbs Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

YMAB is currently covered by 8 analysts with an average price target of $22.22. This is a potential upside of $8.06 (56.92%) from yesterday's end of day stock price of $14.16.

Y mAbs Therapeutics's activity chart (see below) currently has 14 price targets and 41 ratings on display. The stock rating distribution of YMAB is 66.67% BUY, 18.18% HOLD and 15.15% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 54.73% with an average time for these price targets to be met of 155.13 days.

Highest price target for YMAB is $25, Lowest price target is $10, average price target is $22.22.

Most recent stock forecast was given by DAVID NIERENGARTEN from WEDBUSH on 10-Sep-2024. First documented stock forecast 05-May-2020.

Currently out of the existing stock ratings of YMAB, 22 are a BUY (66.67%), 6 are a HOLD (18.18%), 5 are a SELL (15.15%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$23

$8.84 (62.43%)

$13

25 days ago

2/4 (50%)

$9.6 (71.64%)

214

Buy

$22

$7.84 (55.37%)

$22

1 months 22 days ago

3/7 (42.86%)

$11.18 (103.33%)

178

Buy

$25

$10.84 (76.55%)

$26

1 months 22 days ago

3/6 (50%)

$14.18 (131.05%)

367

Sell

$11

$-3.16 (-22.32%)

$5

1 months 22 days ago

4/5 (80%)

$0.18 (1.66%)

186

Hold

$10

$-4.16 (-29.38%)

$12

10 months 20 days ago

3/3 (100%)

$4.75 (90.48%)

114

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is YMAB (Y mAbs Therapeutics) average time for price targets to be met?

On average it took 155.13 days on average for the stock forecasts to be realized with a an average price target met ratio 54.73

Which analyst has the current highest performing score on YMAB (Y mAbs Therapeutics) with a proven track record?

ETZER DAROUT

Which analyst has the current lower performing score on YMAB (Y mAbs Therapeutics) with a proven track record?

WILLIAM PLOVANIC

Which analyst has the most public recommendations on YMAB (Y mAbs Therapeutics)?

Etzer Darout works at BMO and has 10 price targets and 7 ratings on YMAB

Which analyst is the currently most bullish on YMAB (Y mAbs Therapeutics)?

Peter Lawson with highest potential upside - $59.74

Which analyst is the currently most reserved on YMAB (Y mAbs Therapeutics)?

Tessa Romero with lowest potential downside - -$7.16

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?